Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120

Clinical and Experimental Immunology

Volumn 109, Issue 2, 1997, Pages 226-232

  Peet, N M ^a   McKeating, J A ^b   Ramos, B ^a   Klonisch, T ^a   De Souza, J B ^a   Delves, P J ^a   Lund, T ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

AIDs; DNA; HIV gp120 IIIB; IgG subclasses; Vaccination; Vaccine

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 120; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030876747     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4411339.x     Document Type: Article

References (42)

1. Wolff JA, Malone RW, Williams P et al. Direct gene-transfer into mouse muscle in vivo. Science 1990; 247:1465-8.
2. Williams WV, Boyer JD, Merva M et al. Genetic infection induces protective in-vivo immune responses. DNA and Cell Biology 1993; 12:675-83.
3. Liu MA, Hilleman MR, Kuth R, eds. DNA vaccines: a new era in vaccinology. Ann NY Acad Sci 1995; 772.
4. McKeating JA, Shotton C, Cordell J et al. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the 1st and 2nd variable domains of human immunodeficiency virus Type-1 gp120. J Virol 1993; 67:4932-44.
5. Shotton C, Arnold C, Sattentau Q et al. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus Type-1 envelope glycoprotein. J Virol 1995; 69:222-30.
6. McKeating JA, Cordell J, Dean CJ et al. Synergistic interaction between ligands binding to the CD4 binding-site and V3 domain of human immunodeficiency virus Type-I gp120. Virol 1992; 191:7327-42.
7. McKeating JA, Moore JP, Ferguson M et al. Monoclonal-antibodies to the C4 region of human immunodeficiency virus Type-1 gp120 - use in topological analysis of a CD4 binding-site. Aids Res Hum Retrovir 1992; 8:451-9.
8. McKeating JA, Thali M, Furman C et al. Amino-acid-residues of the human immunodeficiency virus Type-I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virol 1992; 190:134-42.
9. Stewart-Tull DES. Freund-type mineral oil adjuvant emulsions. In: Stewart-Tull DES, ed. The theory and practical application of adjuvants. Chichester: John Wiley and Sons Ltd, 1995:1-19.
10. Hunter RL, Olsen MR, Bennett B. Copolymer adjuvants and Titermax. In: Stewart-Tull DES, ed. The theory and practical application of adjuvants. Chichester: John Wiley and Sons Ltd, 1995:51-94.
11. de Souza JB, Playfair JHL. A novel adjuvant for use with a blood-stage malaria vaccine. Vaccine 1995; 13:1316-9.
12. Rudbach JA, Johnson DA, Ulrich JT. Ribi adjuvants: chemistry biology and utility in vaccines for human and veterinary medicine. In: Stewart-Tull DES, ed. The theory and practical application of adjuvants. Chichester: John Wiley and Sons Ltd, 1995:287-314.
13. Campbell JB. Saponins. In: Stewart-Tull DES, ed. The theory and practical application of adjuvants. Chichester: John Wiley and Sons Ltd, 1995:95-128.
14. Lindblad EB. Aluminium adjuvants. In: Stewart-Tull DES, ed. The theory and practical application of adjuvants. Chichester: John Wiley and Sons Ltd, 1995:21-36.
15. Bebbington, CR, Renner G, Thomson S et al. High-level expression of a recombinant antibody from myeloma cells using a glutamine-synthetase gene as an amplifiable selectable marker. Bio-Technol 1992; 10:169-75.
16. Stephens PE, Cockett MI. The construction of a highly efficient and versatile set of mammalian expression vectors. Nucl Acid Res 1989; 17:7110.
17. Wang B, Boyer J, Srikantan V et al. DNA inoculation induces neutralizing immune-responses against human immunodeficiency virus Type-1 in mice and nonhuman-primates. DNA Cell Biol 1993; 12:799-805.
18. Moore JP, Ho DD. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus Type-1 are highly prevalent in sera of infected humans. J Virol 1993; 67:863-75.
19. Bomford R, Stapleton M, Winsor S et al. The control of the antibody isotype response to recombinant human immunodeficiency-virus gp120 antigen by adjuvants. Aids Res Hum Retrovir 1992; 8:1765-71.
20. Poignard P, Klasse PJ, Sattentau QJ. Antibody neutralization of HIV-1. Immunol Today 1996; 17:239-46.
21. Peet N, Delves PJ, De Souza JB et al. The immune-response to HIV gp120 induced by nucleic-acid immunization (NAI). Ann NY Acad Sci 1995; 772:257-60.
22. Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune-responses against human immunodeficiency virus Type-1. Proc Natl Acad Sci USA 1993; 90:4156-60.
23. Wang B, Merva M, Dang KS et al. DNA inoculation induces protective in-vivo immune-responses against cellular challenge with HIV-1 antigen-expressing cells. Aids Res Hum Retrovir 1994; 1:S 35-41.
24. Fuller DH, Haynes JR. A qualitative progression in HIV Type-1 glycoprotein-120-specific cytotoxic cellular and humoral immuneresponses in mice receiving a DNA-based glycoprotein-120 vaccine. Aids Res Hum Retrovir 1994; 10:1433-41.
25. Lu S, Santoro JC, Fuller DH et al. Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody-responses in mice. Virol 1995; 209:147-54.
26. Lasky LA, Groopman JE, Fennie CW et al. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein Science 1986; 233:209-12.
27. Berman PW, Nunes WM, Haffar U. Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus Type-1 in vitro and in continuous cell-lines. J Virol 1988; 62:3135-42.
28. Culp JS, Johansen H, Hellmig B et al. Regulated expression allows high-level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila schneider cells. Bio-Technology 1991; 9:173-7.
29. Li Y, Luo LZ, Thomas DY, Kang CY. Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences Virol 1994; 204:266-78.
30. Niedrig M, Gregersen JP, Fultz PN et al. Immune-response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), 3 different adjuvants and challenge. Vaccine 1993; 11:67-74.
31. Ronco J, Dedieu JF, Marie FN et al. High-titer HIV-1 neutralizing antibody-response of Rhesus macaques to gp160 and env peptides Aids Res Hum Retrovir 1992; 8:1117-23.
32. Powell MF, Eastman DJ, Lim A et al. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein-120 in guinea-pigs. Aids Res Hum Retrovir 1995; 11:203-9.
33. Wu JY, Gardner BH, Murphy CI et al. Saponin adjuvant enhancement of antigen-specific immune-responses to an experimental HIV-1 vaccine. J Immunol 1992; 148:1519-25.
34. Weissburg RP, Berman PW, Cleland JL et al. Characterization of the MN gp120 HIV-1 vaccine-antigen binding to Alum. Pharm Res 1995; 12:1439-46.
35. Bristow RGW, Douglas AR, Skehel JJ, Daniels RS. Analysis of murine antibody-responses to baculovirus-expressed human immunodeficiency virus Type-1 envelope glycoproteins. J Gen Virol 1994; 75:2089-95.
36. Clouse KA, Cosentino LM, Weih KA et al. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol 1991; 147:2892-901.
37. Ebenbichler C, Westervelt P, Carrillo A et al. Structure-functionrelationships of the HIV-1 envelope V3 loop tropism determinant - evidence for 2 distinct conformations. Aids 1993; 7:639-16.
38. Zheng B, Brett SJ, Tite JP et al. Galactose oxidation in the design of immunogenic vaccines. Science 1992; 256:1560-3.
39. Bolmstedt A, Olofsson S, Sjogrenjansson E et al. Carbohydrate determinant NeuAc-Gal-Beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus Type-1 glycoprotein gp120. Gen Virol 1992; 73:3099-105.
40. Doe B, Steimer KS, Walker C. Induction of HIV-1 envelope (gp120)-specific cytotoxic T-lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-Linked Glycans. Eur J Immunol 1994; 24:2369-76.
41. Vancott TC, Bethke FR, Burke DS et al. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995; 155:4100-10.
42. Spear GT, Takefman DM, Sharpe S et al. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutrulization. Virology 1994; 204:609-15.